Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench

被引：2

作者：

Dagogo-Jack, Ibiayi ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Dept Med, Canc Ctr, Boston, MA 02114 USA

来源：

JAMA ONCOLOGY | 2021年 / 7卷 / 11期

关键词：

CRIZOTINIB;

D O I：

10.1001/jamaoncol.2021.3369

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1615 / 1616

页数：2

共 15 条

[1] Clinical Management of Adverse Events Associated with Lorlatinib [J].

Bauer, Todd M. ;

Felip, Enriqueta ;

Solomon, Benjamin J. ;

Thurm, Holger ;

Peltz, Gerson ;

Chioda, Marc D. ;

Shaw, Alice T. .

ONCOLOGIST, 2019, 24 (08) :1103-1110

[2] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

[3] Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study [J].

Gadgeel, S. ;

Peters, S. ;

Mok, T. ;

Shaw, A. T. ;

Kim, D. W. ;

Ou, S. I. ;

Perol, M. ;

Wrona, A. ;

Novello, S. ;

Rosell, R. ;

Zeaiter, A. ;

Liu, T. ;

Nuesch, E. ;

Balas, B. ;

Camidge, D. R. .

ANNALS OF ONCOLOGY, 2018, 29 (11) :2214-2222

[4] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [J].

Gainor, Justin F. ;

Dardaei, Leila ;

Yoda, Satoshi ;

Friboulet, Luc ;

Leshchiner, Ignaty ;

Katayama, Ryohei ;

Dagogo-Jack, Ibiayi ;

Gadgeel, Shirish ;

Schultz, Katherine ;

Singh, Manrose ;

Chin, Emily ;

Parks, Melissa ;

Lee, Dana ;

DiCecca, Richard H. ;

Lockerman, Elizabeth ;

Huynh, Tiffany ;

Logan, Jennifer ;

Ritterhouse, Lauren L. ;

Le, Long P. ;

Muniappan, Ashok ;

Digumarthy, Subba ;

Channick, Colleen ;

Keyes, Colleen ;

Getz, Gad ;

Dias-Santagata, Dora ;

Heist, Rebecca S. ;

Lennerz, Jochen ;

Sequist, Lecia V. ;

Benes, Cyril H. ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. ;

Shaw, Alice T. .

CANCER DISCOVERY, 2016, 6 (10) :1118-1133

[5] Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer A Randomized Clinical Trial [J].

Horn, Leora ;

Wang, Ziping ;

Wu, Gang ;

Poddubskaya, Elena ;

Mok, Tony ;

Reck, Martin ;

Wakelee, Heather ;

Chiappori, Alberto A. ;

Lee, Dae Ho ;

Breder, Valeriy ;

Orlov, Sergey ;

Cicin, Irfan ;

Cheng, Ying ;

Liu, Yunpeng ;

Fan, Yun ;

Whisenant, Jennifer G. ;

Zhou, Yi ;

Oertel, Vance ;

Harrow, Kim ;

Liang, Chris ;

Mao, Li ;

Selvaggi, Giovanni ;

Wu, Yi-Long .

JAMA ONCOLOGY, 2021, 7 (11) :1617-1625

[6] Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study [J].

Horn, Leora ;

Infante, Jeffrey R. ;

Reckamp, Karen L. ;

Blumenschein, George R. ;

Leal, Ticiana A. ;

Waqar, Saiama N. ;

Gitlitz, Barbara J. ;

Sanborn, Rachel E. ;

Whisenant, Jennifer G. ;

Du, Liping ;

Neal, Joel W. ;

Gockerman, Jon P. ;

Dukart, Gary ;

Harrow, Kimberly ;

Liang, Chris ;

Gibbons, James J. ;

Holzhausen, Allison ;

Lovly, Christine M. ;

Wakelee, Heather A. .

CLINICAL CANCER RESEARCH, 2018, 24 (12) :2771-2779

[7] Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial [J].

Huber, Rudolf M. ;

Hansen, Karin H. ;

Paz-Ares Rodriguez, Luis ;

West, Howard L. ;

Reckamp, Karen L. ;

Leighl, Natasha B. ;

Tiseo, Marcello ;

Smit, Egbert F. ;

Kim, Dong-Wan ;

Gettinger, Scott N. ;

Hochmair, Maximilian J. ;

Kim, Sang-We ;

Langer, Corey J. ;

Ahn, Myung-Ju ;

Kim, Edward S. ;

Kerstein, David ;

Groen, Harry J. M. ;

Camidge, D. Ross .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) :404-415

[8] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer [J].

Peters, Solange ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Gadgeel, Shirish ;

Ahn, Jin S. ;

Kim, Dong-Wan ;

Ou, Sai-Hong I. ;

Perol, Maurice ;

Dziadziuszko, Rafal ;

Rosell, Rafael ;

Zeaiter, Ali ;

Mitry, Emmanuel ;

Golding, Sophie ;

Balas, Bogdana ;

Noe, Johannes ;

Morcos, Peter N. ;

Mok, Tony .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09) :829-838

[9] Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial [J].

Planchard, David ;

Kim, Tae Min ;

Mazieres, Julien ;

Quoix, Elisabeth ;

Riely, Gregory ;

Barlesi, Fabrice ;

Souquet, Pierre-Jean ;

Smit, Egbert F. ;

Groen, Harry J. M. ;

Kelly, Ronan J. ;

Cho, B. C. ;

Socinski, Mark A. ;

Pandite, Lini ;

Nase, Christine ;

Ma, Bo ;

D'Amelio, Anthony, Jr. ;

Mookerjee, Bijoyesh ;

Curtis, C. Martin, Jr. ;

Johnson, Bruce E. .

LANCET ONCOLOGY, 2016, 17 (05) :642-650

[10]

Schoenfeld AJ, 2020, CLIN CANCER RES, V26, P2654, DOI [10.1158/10780432.CCR-19-3563, 10.1158/1078-0432.CCR-19-3563]

← 1 2 →